Finally, these results were corroborated in a more clinically relevant model of APC mutation (cAPC), which displayed nearly identical inflammatory phenotypes, further substantiating the TGFβ pathway as anti-inflammatory in colon cancer. The gene discussed is TGFB1; the disease is malignant colon neoplasm.